Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other financing activities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Other financing activities for 11 consecutive years, with $55000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 34.15% to $55000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $67000.0 through Dec 2025, up 28.85% year-over-year, with the annual reading at $67000.0 for FY2025, 28.85% up from the prior year.
  • Other financing activities for Q4 2025 was $55000.0 at Niagen Bioscience, up from $6000.0 in the prior quarter.
  • The five-year high for Other financing activities was $75000.0 in Q4 2023, with the low at $3000.0 in Q2 2021.
  • Average Other financing activities over 5 years is $34636.4, with a median of $41000.0 recorded in 2024.
  • Peak annual rise in Other financing activities hit 231.58% in 2021, while the deepest fall reached 80.0% in 2021.
  • Over 5 years, Other financing activities stood at $63000.0 in 2021, then dropped by 1.59% to $62000.0 in 2022, then rose by 20.97% to $75000.0 in 2023, then tumbled by 45.33% to $41000.0 in 2024, then skyrocketed by 34.15% to $55000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $55000.0, $6000.0, and $6000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.